FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.
You may also be interested in...
McClellan To Lead June 13 CMS Forum On Drug Data Strategies
FDA and AHRQ officials will discuss ways Medicare data could help improve medical decisions. The Drug Data Strategy plan combines Part D drug data with Parts A and B medical treatment data.
McClellan To Lead June 13 CMS Forum On Drug Data Strategies
FDA and AHRQ officials will discuss ways Medicare data could help improve medical decisions. The Drug Data Strategy plan combines Part D drug data with Parts A and B medical treatment data.
Drug Safety Surveillance Based On Medicare Data Should Top List Of FDA Priorities
Implementation of the Medicare drug benefit provides an opportunity for an active surveillance system to collect drug safety data, Drug Safety & Risk Management Advisory Committee members say. Active surveillance can act as a safety net for FDA's adverse events signaling system.